These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38691057)

  • 1. Metronomic Chemotherapy for Pediatric Refractory Solid Tumors: A Retrospective Single-center Study.
    Sakurai Y; Iwasaki F; Hirose A; Matsumoto N; Miyagawa N; Keino D; Yokosuka T; Hamanoue S; Yanagimachi M; Shiomi M; Goto S; Tanaka M; Tanaka Y; Nozawa K; Goto H
    J Pediatr Hematol Oncol; 2024 Jul; 46(5):233-240. PubMed ID: 38691057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
    Pramanik R; Agarwala S; Gupta YK; Thulkar S; Vishnubhatla S; Batra A; Dhawan D; Bakhshi S
    JAMA Oncol; 2017 Sep; 3(9):1222-1227. PubMed ID: 28384657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metro-SMHOP 01: Metronomics combination with cyclophosphamide-etoposide and valproic acid for refractory and relapsing pediatric malignancies.
    El Kababri M; Benmiloud S; Cherkaoui S; El Houdzi J; Maani K; Ansari N; Khoubila N; Kili A; El Khorassani M; Madani A; Tazi MA; Ahid S; Hessissen L; Quessar A; Harif M; Khattab M; André N
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28508. PubMed ID: 32658380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor.
    Heng-Maillard MA; Verschuur A; Aschero A; Dabadie A; Jouve E; Chastagner P; Leblond P; Aerts I; De Luca B; André N
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27693. PubMed ID: 30920117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
    Devadas SK; Banavali S
    Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.
    Zapletalova D; André N; Deak L; Kyr M; Bajciova V; Mudry P; Dubska L; Demlova R; Pavelka Z; Zitterbart K; Skotakova J; Husek K; Martincekova A; Mazanek P; Kepak T; Doubek M; Kutnikova L; Valik D; Sterba J
    Oncology; 2012; 82(5):249-60. PubMed ID: 22538363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
    Qayed M; Cash T; Tighiouart M; MacDonald TJ; Goldsmith KC; Tanos R; Kean L; Watkins B; Suessmuth Y; Wetmore C; Katzenstein HM
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28134. PubMed ID: 31876107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package.
    Bahl A; Bakhshi S
    Indian J Pediatr; 2012 Dec; 79(12):1617-22. PubMed ID: 22544675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of a pediatric metronomic 4-drug regimen.
    André N; Abed S; Orbach D; Alla CA; Padovani L; Pasquier E; Gentet JC; Verschuur A
    Oncotarget; 2011 Dec; 2(12):960-5. PubMed ID: 22156656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors.
    Launay S; Sabatier R; Brunelle S; Esterni B; Tarpin C; Viret F; Gravis G; Cappiello M; Provansal M; Extra JM; Bertucci F; Viens P; Goncalves A
    Anticancer Res; 2016 Jan; 36(1):293-9. PubMed ID: 26722056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All.
    André N; Orbach D; Pasquier E
    Trends Cancer; 2020 Oct; 6(10):819-828. PubMed ID: 32601045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.
    Berthold F; Hömberg M; Proleskovskaya I; Mazanek P; Belogurova M; Ernst A; Sterba J
    Pediatr Hematol Oncol; 2017 Aug; 34(5):308-319. PubMed ID: 29148865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.
    Fousseyni T; Diawara M; Pasquier E; André N
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):31-4. PubMed ID: 21164360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
    Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
    J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
    Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
    Hernández-Marqués C; Lassaletta-Atienza A; Ruiz Hernández A; Blumenfeld Olivares JA; Arce Abaitua B; Cormenzana Carpio M; Madero Lopez L
    An Pediatr (Barc); 2013 Aug; 79(2):68-74. PubMed ID: 23332825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
    De Pasquale MD; D'Angelo P; Crocoli A; Boldrini R; Conte M; Bisogno G; Spreafico F; Inserra A; Biasoni D; Dall'Igna P; Siracusa F; Miele E; Terenziani M
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28125. PubMed ID: 31850649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study.
    André N; Rome A; Coze C; Padovani L; Pasquier E; Camoin L; Gentet JC
    Clin Ther; 2008 Jul; 30(7):1336-40. PubMed ID: 18691994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic palliative chemotherapy in locally advanced, recurrent and metastatic head-and-neck cancer: A single-arm, retrospective study of a regional cancer center of North India (Asia).
    Harsh KK; Maharia SR; Nirban RK; Khatri P; Beniwal S; Kumar HS; Jakhar SL
    J Cancer Res Ther; 2020; 16(3):559-564. PubMed ID: 32719267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
    Robison NJ; Campigotto F; Chi SN; Manley PE; Turner CD; Zimmerman MA; Chordas CA; Werger AM; Allen JC; Goldman S; Rubin JB; Isakoff MS; Pan WJ; Khatib ZA; Comito MA; Bendel AE; Pietrantonio JB; Kondrat L; Hubbs SM; Neuberg DS; Kieran MW
    Pediatr Blood Cancer; 2014 Apr; 61(4):636-42. PubMed ID: 24123865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.